

REMARKS

This amendment is being filed prior to examination.

Claims 7, 8, 10 and 12 have been amended herein and new dependable claims 13-16 have been added as presented in the attached Appendix in order to obviate the need for multiple dependencies.

An early favorable allowance of the claims remaining in the present application is earnestly solicited.

Respectfully submitted,
For applicant

By: 


Richard B. Klar
Registration No. 31,385

Dated: June 15, 2001

Anderson, Kill & Olick P.C.
1251 Avenue of the Americas
New York, New York 10020-1182
(212) 278-1000

CERTIFICATE OF MAILING

I hereby certify that this PRELIMINARY AMENDMENT and PATENT APPLICATION W/ATTACHMENTS are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on June 15, 2001 Mailing Label Number: EL 763937985 US, and is addressed to the Commissioner for Patents, Box Patent Application, Washington, DC 20231.


Audrey de Souza

Amended Claims:

7. A process for preparing the protein or fragment of claim 3 comprising culturing the microorganism of claim 5.
8. A kit for diagnosis of cancer which comprises the protooncogene or fragment of claim 1.
10. An anti-sense gene having a base sequence which is complementary to the sequence of the full or partial mRNA transcribed from the protooncogene or fragment of claim 1 and being capable of binding the mRNA to inhibit the expression of said protooncogene or fragment.
12. A process for treating or preventing cancer in humans which comprises administering a therapeutically effective amount of the anti-sense gene of claim 10 to the human.

New Claims:

13. A process for preparing the protein or fragment of claim 3 comprising culturing the microorganism of claim 6.

14. A kit for diagnosis of cancer which comprises the protooncogene or fragment of claim 2.

A4
Cont

15. An anti-sense gene having a base sequence which is complementary to the sequence of the full or partial mRNA transcribed from the protooncogene or fragment of claim 2 and being capable of binding the mRNA to inhibit the expression of said protooncogene or fragment.

16. A process for treating or preventing cancer in humans which comprises administering a therapeutically effective amount of the anti-sense gene of claim 11 to the human.